Source: Healio News
Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated results from the ICARIA-MM study.
The data, presented at the ASCO Annual Meeting, demonstrated a strong trend in OS benefit in the istuximab (Sarclisa, Sanofi-Aventis) regimen arm, with approximately 7-month improvement in median OS.
Based on results from the ICARIA-MM study and from the IKEMA study, istuximab was approved in combination with pomalidomide